lundi 18 mai 2020

Onco Actu du 18 mai 2020


3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE



For Women with Breast Cancer, Regular Exercise May Improve Survival [NCI]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Genome-wide pattern found in tumors from brain cancer patients predicts life expectancy [University of Utah]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Looking for first-in-class glory, Boehringer Ingelheim acquires two preclinical cancer drugs from Versant-backed biotech [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Bristol Myers Squibb finally breaks into first-line lung cancer with Opdivo-Yervoy nod [Fierce Pharma]











U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1% [BMS]











FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) [FDA]










5.2 PHARMA



Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutant metastatic non-small cell lung cancer [AstraZeneca]











5.2.3 PHARMA - ÉCONOMIE



ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon [Xconomy]











5.2.6 PHARMA - BIOTECH



Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder [Fierce Pharma]











After a PhIII failure, the FDA delivers Blueprint an expected CRL [EndPoints]











5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - RUCAPARIB



Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy [Clovis Oncology]











FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer [FDA]










5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - RIPRETINIB



Deciphera Pharmaceuticals Wins Early FDA Nod for GI Cancer Treatment [Xconomy]











FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [Deciphera]











FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors [FDA]










5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms [Novartis]











5.5.15 ASCO (BIOPSIES LIQUIDES)



Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer [Guardant Health]











5.9.3 EHA



AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio [AbbVie]











6.1 OBSERVATION



Geography of childhood cancer in Switzerland studied [University of Bern]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Protecting “covid-protected” cancer hubs [BMJ]










Treatment Guidance for Lung Cancer Patients During the COVID-19 Pandemic - Journal of Thoracic Oncology Publishes Comprehensive Overview [IASLC]